Sterile Compounding

  • Home /
  • Sterile Compounding
Injectables

Injectables

Examples of sterile injections that can be compounded by prescription order include:

  • Intracavernosal injections of papaverine and phentolamine, sometimes with prostaglandin E1 (“tri-mix”) in customized doses.
Ophthalmics

Ophthalmics

We can compound sterile ophthalmic drops, ointments, sprays, injections and pre-op solutions, including anesthetics, antibiotics, antioxidants, antivirals, cataract therapies, corticosteroids, ophthalmic decongestants, miotics, mydriatics, and lubricants. Preparations can contain a single drug or a combination in the most appropriate strength and concentration for a specific use, such as fortified antibiotic or pre-op drops.

Erectile Dysfunction

Erectile Dysfunction

 

“Tri-Mix” Injection for Erectile Dysfunction

Men with erectile dysfunction (ED) who used triple therapy (papaverine/phentolamine/prostaglandin-E1) by intracavernosal injection (ICI) and then changed to oral sildenafil found they had a greater preference than expected for triple therapy. Overall, the erection quality with ICI was better than that with sildenafil.1 Fear of pain with intracavernosal injection (ICI) therapy may discourage its use. Yet, findings from a Cleveland Clinic study show that in the majority of ED patients, discomfort is minimal.2

Treatment with self-injections of vasoactive drugs in men with diabetes (both type 1 and type 2) and severe ED is a safe and effective alternative in the long term. The key is adjustment of the therapeutic method and dosage to optimal levels for satisfactory erections.3

Veterinary

Veterinary

Examples of sterile veterinary preparations that can be compounded by prescription order include:

  • Methocarbomol
  • Mitomycin C
  • Guaifenesin
  • Ophthalmic Preparations

Pluronic Gels

Platinum based chemotherapy drugs (cisplatin, carboplatin, oxiliplatin) are frequently used in the treatment of neoplasia and other solid tumors in both humans and animals. In spite of positive results achieved in these cases, therapy is often limited by serious systemic adverse effects (nephrotoxicity, myelosuppression) and also by emergence of tumor resistance. By delivering these drugs locally through intratumoral or regional administration, systemic toxicities have been reduced, but the problem of drug resistance remains a major issue.

WHAT PATIENTS ARE SAYING

We Affiliate With

Our focus is providing the best possible treatments available to patients